News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tranzyme Pharma and Norgine Complete Enrollment in First of Two Pivotal Phase 3 Trials of Ulimorelin


12/7/2011 9:50:06 AM

RESEARCH TRIANGLE PARK, N.C., Dec. 7, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) and Norgine B.V. today announced completion of patient enrollment in ULISES 007, the first of two Phase 3 pivotal trials of ulimorelin for the acceleration of gastrointestinal (GI) recovery in patients undergoing partial bowel resection. There are an estimated 1 million patients in the U.S. at high risk each year for delayed GI recovery after surgery, including approximately 385,000 bowel resection surgeries.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES